tradingkey.logo
tradingkey.logo
Buscar

Evolus Inc

EOLS
Añadir a la lista de seguimiento
6.900USD
+0.160+2.37%
Cierre 07/02, 13:00ETCotizaciones retrasadas 15 min
454.29MCap. mercado
PérdidaP/E TTM

Más Datos de Evolus Inc Compañía

Evolus, Inc. is a performance beauty company. Its primary market is the cash-pay aesthetic market, which consists of medical products. Its product candidates represent two of the product categories within medical aesthetics, injectable neurotoxins and injectable hyaluronic acid gels. Its product candidates include Jeuveau and Evolysse. Jeuveau is its commercially available proprietary 900 kilodalton (kDa), purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe glabellar lines, also known as frown lines, in adults. Jeuveau offers a 900kDa botulinum toxin alternative to BOTOX (onabotulinumtoxinA). Jeuveau is available in the United States, Canada, and certain European markets. Evolysse is a line of hyaluronic acid dermal fillers which utilizes first-generation cold technology. The line includes a variety of products, including mid face, nasolabial folds, lips and eyes in the United States and Europe.

Información de Evolus Inc

Símbolo de cotizaciónEOLS
Nombre de la empresaEvolus Inc
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMoatazedi (David)
Número de empleados332
Tipo de seguridadOrdinary Share
Fin del año fiscalFeb 08
Dirección520 Newport Center Dr Ste 1200
CiudadNEWPORT BEACH
Bolsa de valoresNASDAQ OMX - NASDAQ BASIC
PaísUnited States of America
Código postal92660-7022
Teléfono19492844555
Sitio Webhttps://www.evolus.com/
Símbolo de cotizaciónEOLS
Fecha de salida a bolsaFeb 08, 2018
Director ejecutivoMoatazedi (David)

Ejecutivos de Evolus Inc

Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--
Ms. Karah Parschauer, J.D.
Ms. Karah Parschauer, J.D.
Independent Director
Independent Director
--
--
Mr. Nareg Sagherian
Mr. Nareg Sagherian
Investor Relations
Investor Relations
--
--
Mr. Albert G. White, III
Mr. Albert G. White, III
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Mr. Vikram Malik
Mr. Vikram Malik
Independent Chairman of the Board
Independent Chairman of the Board
243.01K
-28.17%
Ms. Tatjana Mitchell
Ms. Tatjana Mitchell
Chief Financial Officer
Chief Financial Officer
226.09K
+53.73%
Mr. David Moatazedi
Mr. David Moatazedi
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
105.11K
-128.12%
Mrs. Brady Stewart
Mrs. Brady Stewart
Independent Director
Independent Director
88.63K
-43.10%
Mr. David N. Gill
Mr. David N. Gill
Independent Director
Independent Director
41.33K
-92.42%
Dr. Rui L. Avelar, M.D.
Dr. Rui L. Avelar, M.D.
Chief Medical Officer, Head - Research and Development
Chief Medical Officer, Head - Research and Development
--
--

Preguntas frecuentes

¿Quiénes son los cinco principales accionistas de Evolus Inc?

Los cinco principales accionistas de Evolus Inc son: Mr. Vikram Malik

¿Cuántas instituciones poseen acciones de Evolus Inc (EOLS)?

A fecha de 2026Q1, 391 instituciones poseen acciones de Evolus Inc, con un valor de mercado combinado de aproximadamente 50.03M, lo que representa el 75.98% del total de acciones. En comparación con el 2025Q4, el accionariado institucional ha aumentado en -16021350.00.